Mandate

VINGE ADVISES SBAB IN CONNECTION WITH ACQUISITION OF BOOLI

December 11, 2015

Vinge has advised SBAB in connection with the acquisition of the entire issued share capital in Booli Search Technologies AB (“Booli”). Completion in respect of 67% of the shares will take place in January 2016 and it is intended that the remaining 33% will be acquired subsequently. Booli develops products and services directed to the housing market. The services include, among other things, booli.se, one of Sweden’s largest search sites for residential properties with more than 270 000 unique visitors per week, and Hittamäklare.se, an estate agents comparison site for private individuals wishing to sell their residence. Booli will be a subsidiary of SBAB and will continue as an independent enterprise under the trademark Booli.

Vinge’s team consisted of partner Daniel Rosvall together with, among others, associates Maria Dahlin, Manne Bergström, Karin Virding, Tomas Forsgren, Karin Isacson and Niklas Thorgerzon as well as project assistants Anna Hellof and Caroline Skymberg.

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024